Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Silver. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985228 | 0.97 | CA12 (0.42) | CA12CA1CA9CES2CES1 | |
| Potassium Ion SCHEMBL3687008 | 0.93 | CA12 (0.40) | CA12CA1CA9CES2CES1 | |
| SCHEMBL1451848 | 0.93 | CA12 (0.40) | CA12CA1CA9CES2CES1 | |
| Lithium Ion SCHEMBL1452517 | 0.93 | CA12 (0.40) | CA12CA1CA9CES2CES1 | |
| SCHEMBL6683171 | 0.93 | CA12 (0.40) | CA12CA1CA9CES2CES1 | |
| SCHEMBL1451786 | 0.93 | CA12 (0.40) | CA12CA1CA9CES2CES1 | |
| SCHEMBL20080910 | 0.81 | RAPGEF4 (0.39) | CA12CA1CA9 | |
| SCHEMBL6913013 | 0.77 | — | — | |
| SCHEMBL8168070 | 0.77 | CA12 (0.46) | CA12CA1CA9 | |
| SCHEMBL29846310 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671210-B2 | Process for production of optically active cyclopropanecarboxylate compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| EP-1783130-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2009-12-30 | — | — | EP | disclosed |
| US-20090048450-A1 | Process for production of optically active cyclopropanecarboxylate compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1783130-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048450-A1 | Process for production of optically active cyclopropanecarboxylate compound | CBR3, C9, CBR1 | CA12 853/4885CA1 659/4885CA9 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.